Literature DB >> 1344575

Pelviscopic uterine surgery.

L Mettler1, K Semm.   

Abstract

About 15-20% of the time uterine surgery via laparotomy is replaced in our department by operative pelviscopy. Of these, in reference to myoma surgery, about 70% were tackled with operative pelviscopy and a laparotomy was avoided. This allows the preservation of the uterus, especially for those women who desire to bear children in the future. Organ-preserving, minimally invasive surgery is the current accepted operative ideal. Postoperative sequelae like adhesion formation, subacute intestinal obstruction, and chronic abdominal pain are thus decreased. The importance of correct and safely functioning equipment and instruments cannot be overstressed for optimal results. A closed drain, i.e., the Robinson drainage system, can be kept in place for at least 12-24 h to check the postoperative ooze. In two cases of extensive ooze, repeat pelviscopy was performed within 12 h and hemostasis was achieved by the use of endosutures and endocoagulation.

Entities:  

Mesh:

Year:  1992        PMID: 1344575     DOI: 10.1007/bf00591183

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  2 in total

1.  Safety in laparoscopy.

Authors:  R Palmer
Journal:  J Reprod Med       Date:  1974-07       Impact factor: 0.142

2.  Technical progress in pelvic surgery via operative laparoscopy.

Authors:  K Semm; L Mettler
Journal:  Am J Obstet Gynecol       Date:  1980-09-15       Impact factor: 8.661

  2 in total
  2 in total

1.  Robotic applications in reproductive endocrinology and infertility.

Authors:  Julie Sroga; Sejal Dharia Patel
Journal:  J Robot Surg       Date:  2008-02-28

2.  The Improvement of Laparoscopic Surgical Skills Obtained by Gynecologists after Ten Years of Clinical Training Can Reduce Peritoneal Adhesion Formation during Laparoscopic Myomectomy: A Retrospective Cohort Study.

Authors:  Valerio Mais; Michele Peiretti; Luigi Minerba
Journal:  Biomed Res Int       Date:  2017-12-19       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.